APPLE ROBERT F 4

What Happened
Robert F. Apple, a director of Kazia Therapeutics Ltd. (KZIA), was granted 75,000 options over ADSs on January 8, 2026. The options were granted for no consideration and recorded on the Form 4 as an award (derivative) with $0 cash paid. The exercise (strike) price is $6.78 per ADS (set to the Nasdaq closing price on Jan 8, 2026). The options vest on January 8, 2027 and expire January 8, 2029.

Key Details

• Transaction date: January 8, 2026; Form 4 filed July 8, 2026 (the filing is several months late).
• Grant: 75,000 options; exercise price $6.78 per ADS (total exercise cost if fully exercised = $508,500).
• Consideration: granted for no cash (reported acquisition value = $0).
• Vesting/expiry: vests January 8, 2027; expires January 8, 2029.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: award was board-/Remuneration Committee‑approved; strike set by reference to Nasdaq close on Jan 8, 2026.
• Timeliness: filing date is July 8, 2026 for a Jan 8, 2026 grant — this is a late Form 4 filing.

Context
This is a stock‑option grant (a derivative award), not an immediate purchase or sale. Options give the holder the right to buy ADSs in the future at the $6.78 strike once vested; they do not create immediate share ownership or proceeds unless exercised. Late Form 4 filings do not alter the grant itself but can raise compliance questions for the company or the insider.